Latest Breaking News On - Global head oncology - Page 2 : comparemela.com

GSK s Belantamab Mafodotin Shows Promise as Second-Line Treatment for Multiple Myeloma in Phase III Trial

GSK s Belantamab Mafodotin Shows Promise as Second-Line Treatment for Multiple Myeloma in Phase III Trial
news.europawire.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news.europawire.eu Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomGsk belantamab mafodotinTim foleyHesham abdullahKyowa kirin groupBiowa incSeagen incMafodotin shows promiseSecond line treatmentMultiple myelomaSenior vice presidentGlobal head oncologyKyowa kirinAnnual reportGlobal corporate media

GSK positive headline results from DREAMM-7 phase III clinical trial

GSK positive headline results from DREAMM-7 phase III clinical trial

Hesham abdullahData monitoring committeeIndependent data monitoring committeeSenior vice presidentGlobal head oncologyMultiple myeloma

GSK : Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer - Form 6-K -October 30, 2023 at 07:13 am EDT

a6268r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER.

United kingdomUnited statesCity ofTreasure islandUnited kingdom generalNick stoneTim foleyCamilla campbellMick readeyJames dodwellSteph mountifieldKathleen quinnJeff mclaughlinLyndsay meyerDan smithJosh williams

Dostarlimab Plus Chemo Provides OS Benefit in Primary Advanced or Recurrent Endometrial Cancer

The addition of dostarlimab to carboplatin plus paclitaxel followed by dostarlimab monotherapy significantly improved overall survival compared with placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.

Hesham abdullahGlobal head oncologyThe addition of dostarlimab to carboplatin plus paclitaxel followed by monotherapyPatients with primary advanced or recurrent endometrial cancerRuby engot en6 gog3031 nsgo trial